.79] vs PBO:2.36 ng/mL [range 0.02; 2254.50]). Lastly, AAP significantly delayed med time to PSA progression as compared to PBO (33.2 mo vs 7.4 mo, respectively; HR: 0.3, p < 0.0001) and the time to PSA progression strongly correlated with rPFS (Kendall's tau ¼ 0.9211) and OS (Kendall's tau ¼ 0.666). Conclusions: Treatment of high-risk mHSPC with ADTþAAP demonstrates a significant depth of PSA response that strongly correlates with long-term outcomes of rPFS and OS.
Division of Oncogenomics and Internal Medicine, Netherlands Cancer Institute (NKI-AVL), Amsterdam, Netherlands, 10 Laboratory of Experimental Urology, Radboud University Medical Centre Nijmegen, Nijmegen, Netherlands, 11 Medical Oncology, Erasmus University Medical Center / Center for Personalized Cancer Therapy, Rotterdam, Netherlands Background: A comprehensive assessment of biopsies from metastatic prostate cancer (mPCa) patients (pts) may identify a molecular subset of pts susceptible for immune checkpoint (IC) blockade (ICB). Methods: 148 biopsies and germline DNA from 145 mPCa pts were whole genome sequenced (WGS) at an average of 114x and 38x. Tumour mutational (mut) burden (TMB) was defined as number of somatic single nucleotide variants and InDels per Mb of the genome, known mut signatures (Alexandrov, Nature 2013) extracted by nonnegative least squares regression as well as recurrent mutations reported in mismatch repair (MMR) pts (Kim, Cell 2013). Selected pts with high TMB were further evaluated for; (a) MMR protein expression; (b) multiplex intratumoural (IT) immune cell phenotyping (VECTRA); (c) multiplex IC expression (VECTRA); (d) 8-color flow cytometry blood immune cell phenotyping, with high TMB pts compared with low TMB pts. Pts receiving anti-PD-1 ICB had additional immune phenotyping at C2, C3, C4 and at progression; 3 pts had post-progression biopsies analyzed. Results: The median TMB was 2.9 (IQR 2.2 -3.9); 12 pts (8.3%) had high TMB (>10 mut/Mb). In 11/12 pts with high TMB, corresponding MMR deficiency (MMRd) signatures (6, 15, 20 and 21) were identified. Recurrent mut in MMR genes were detected MSH2/MSH6, MSH3, MLH1; other recurrent mut were in POLE, and frameshift mut enriched (p < 0.001) in genes including TGFBR2, CLOCK, RPL22 and JAK1. Immunohistochemistry confirmed MMRd in 6/6 biopsies and in matched primary tissue in 5/5 evaluable pts. Five pts were referred for germline testing without MMR mut. A trend for increased IT CD3þ cells were seen in MMRd (p ¼ 0.06); no relation was found between TMB and tumour PD-L1 expression. Pts were treated with anti-PD-1 ICB, with PSA>50% decline of 57% of hTMB pts (n ¼ 7), and a significant decline in circulating T-cell populations during ICB, including CD4þPD-1 þ (p ¼ 0.02) and CD8þPD-1 þ (p ¼ 0.007). Response rate, duration of response, genomic and immune correlates will be presented for pts with low and high TMB.
Conclusions: 8% of mPCa pts display a high TMB with recurrent somatic mut in MMR genes and POLE. MMRd appears early in PCa evolution. High TMB pts witness a high response rate to monotherapy anti-PD-1 ICB. Background: PSMA is selectively overexpressed in advanced PC with upregulation by androgen receptor (AR) pathway dysregulation; limited expression in other organs. PC is radiosensitive with dose-response data. Dose-fractionation may allow delivery of higher total doses with less radioresistance than doses several weeks to months apart. Small molecule PSMA inhibitor ligands can be successfully radiolabeled and have been used for imaging and treatment, but no dose-escalation study has been performed. Methods: Progressive mCRPC following at least 1 potent AR-targeted agent (e.g. abi/ enza) and docetaxel (or unfit/refuse chemo) without limit of # prior therapies provided adequate organ function, ECOG performance status 0-2, and without preselection for PSMA expression were enrolled. Treatment was a single cycle of fractionated dose 177 Lu-PSMA-617 on D1 and D15 starting at 7.4 GBq with planned escalation up to 22.2 GBq in modified 3 þ 3 dose-escalation. Primary endpoint is determination of dose limiting toxicity (DLT) and recommended phase 2 dose (RP2D) with secondary efficacy endpoints. Pre-and post-treatment 68Ga-PSMA11 PET/CT and post-treatment 177Lu-PSMA-617 imaging was performed in addition to standard serial CT and bone scans.
Results: 29 men with median age 70 (range 56-87), median PSA 98.9 (range 6-2222) were treated. 93% with bone, 25% node, 14% lung, 7% liver, 7% other visceral metastases. 52% with at least 1 chemo, 45% >1 prior potent AR therapy, 17% with Ra223, 10 sip-T, 3% 177Lu-J591. Background: Intraductal carcinoma of the prostate (IDC-P) is an adverse prognosticator of prostate cancer (PCa). However, the role of IDC-P proportion and architectural patterns in patient outcome remain unclear.
Methods: Data of 644 de novo metastatic PCa (mPCa) patients between 2010-2017 were retrospectively analyzed. IDC-P was identified from 12-core prostate biopsy. IDC-P proportion were calculated. IDC-P were classified into two architectural patterns according to the 2016 WHO classification: pattern-1 (loose cribriform or micropapillary) and pattern-2 (solid or dense cribriform). Propensity-score matching (PSM) was conducted to balance the baseline characteristics between patients with and without IDC-P. Kaplan-Meier curves and COX regression were utilized in survival analysis. The endpoints were castration-resistant PCa free survival (CFS) and overall survival (OS). 
